An NIH-funded analysis suggests higher doses of buprenorphine were associated with lower rates of emergency department visits or use of inpatient services related to behavioral health.
An NIH-funded analysis suggests higher doses of buprenorphine were associated with lower rates of emergency department visits or use of inpatient services related to behavioral health.
Read More
Only a small percentage of buprenorphine prescriptions go unfilled, even when patients have to pay more out of pocket, suggesting the need to remove other barriers to continuous prescriptions.
Read More
Starting extended-release naltrexone within five to seven days of seeking treatment improves success rates for opioid addiction compared to the standard 10-15 days, but requires closer medical supervision.
Read More
Starting buprenorphine treatment for opioid use disorder through telehealth increased the likelihood of staying in treatment longer, a federally funded study found.
Read More
Patients prescribed the FDA-recommended dose were significantly more likely to discontinue treatment over 180 days compared to those prescribed a higher dose, an NIH-supported study found.
Read More
The injectable is approved in both weekly and monthly formulations at varying doses, including lower doses that may be appropriate for those who do not tolerate higher doses.
Read More
UCLA Health seeks participants for a first-of-its-kind study using injectable buprenorphine to treat methamphetamine use disorder and opioid co-use.
Read More
